Last updated: February 16, 2026
What Is the Current Market Size and Growth?
The global intrauterine device (IUD) market was valued at approximately $2.8 billion in 2021 and is projected to reach around $4.5 billion by 2028, growing at a compound annual growth rate (CAGR) of 7.2% (CAGR from 2022-2028). Progestin-containing IUDs represent the predominant segment due to their enhanced contraceptive efficacy and non-reversible effects. In 2021, progestin IUDs accounted for roughly 65% of the market share.
What Are the Key Drivers and Barriers?
Drivers:
- Increasing demand for long-acting reversible contraception (LARC): The convenience and effectiveness of progestin IUDs support adoption.
- Rising awareness and government initiatives: Policies promoting contraception access and family planning increase usage.
- Better tolerability and safety profile: Reduced incidence of systemic side effects compared to traditional hormonal methods.
- Technological advancements: Developments in IUD design improve comfort and reduce complications.
Barriers:
- High upfront cost: The device and insertion procedures are expensive initially, limiting access in some regions.
- Limited provider training: Proper insertion requires specialized skills, restricting availability in some markets.
- Patient hesitancy: Due to misconceptions or fears of side effects, particularly concerning hormonal components.
How Does the Patent Landscape Look?
Patent Timeline and Expirations
The patent landscape for progestin IUDs has evolved over the past three decades. The earliest patents for progestin-releasing IUDs date back to the late 1980s, beginning with Norplant-related innovations. Key patents include:
-
Levonorgestrel-releasing IUD patents (early 1990s): Filed by Teva Pharmaceuticals and Schering-Plough. These patents covered composition, delivery mechanisms, and device design.
-
Kyleena and Mirena patents (2000s): Bayer Pharmaceuticals' Mirena (2000) and Kyleena (2016) have patents covering the specific release formulations, device design, and usage.
Patent Status and Expiration
Many foundational patents for first-generation devices like Mirena (patents filed in the 1990s, expiring around 2010-2015) have expired or are nearing expiry. This has led to a wave of generic and biosimilar devices entering the market.
Current active patents primarily cover:
- Novel delivery system improvements.
- Reduced side effects.
- Application methods.
These patents typically lapse between 2025 and 2030, opening opportunities for generic manufacturers.
Patents in Development
Companies are investing in:
- Smaller, less invasive devices.
- Extended-release formulations.
- Multi-purpose systems that combine contraception with other health benefits.
Patent filings for these innovations are primarily in the US, Europe, and China, with filings increasing over the last five years.
Who Are the Major Market Players?
- Bayer AG: Manufacturer of Mirena, Kyleena, and other hormonal IUDs. Holds key patents that protect market share until 2025-2030.
- CooperSurgical: Offers ParaGard (non-hormonal copper IUD) and is developing progestin-based devices.
- HTA (Health Technology Assessment) agencies: Influence market access through coverage and reimbursement policies.
- Emerging companies: Focus on generic versions or innovative delivery systems.
What Is the Regulatory Environment?
- US Food and Drug Administration (FDA): Approves new IUDs based on safety and efficacy data. Most progestin IUDs are approved under the 510(k) or Premarket Approval (PMA) pathways.
- European Medicines Agency (EMA): Similar approval process, with some country-specific variations.
- Global markets: Regulatory processes are evolving, impacting the timing of device launches.
Future Trends and Opportunities
- Expansion into emerging markets where contraceptive access is increasing.
- Development of combination devices offering contraception with contraception and fertility monitoring.
- Increasing focus on biodegradable and more comfortable IUDs to improve patient acceptance.
- Patent expirations will drive price competition, enabling wider adoption.
Key Takeaways
The market for progestin-containing IUDs is expanding, driven by demand for long-term contraception, technological innovation, and policy support. Patent expiry of early-generation devices creates market entry opportunities for generics while current patents on device innovations restrict new entrants. Market growth depends on regulatory approvals, provider training, and patient acceptance, especially where cost remains a barrier.
FAQs
Q1: How long do patents typically last for progestin IUDs?
Patents generally last 20 years from the filing date. Most foundational patents filed in the 1990s have expired or will expire between 2025-2030, enabling generic competition.
Q2: What are the major advantages of progestin IUDs over non-hormonal devices?
Progestin IUDs reduce menstrual bleeding, provide contraception for up to 5-7 years, and have higher effectiveness rates than non-hormonal devices like copper IUDs.
Q3: Is the patent landscape expected to change with new devices?
Yes. Innovations such as biodegradable materials and combined contraceptive/monitoring devices are subject to new patents, which will shape future market dynamics.
Q4: What are the regulatory challenges for new progestin IUDs?
Manufacturers must demonstrate safety, efficacy, and tolerability through clinical trials. Approval processes vary globally, which can delay market entry.
Q5: How might patent expirations impact market prices?
Patent expirations typically lead to price reductions due to increased competition, improving affordability and adoption in cost-sensitive markets.
References
[1] MarketWatch. "Global Intrauterine Device Market Report." 2022.
[2] Grand View Research. "Long-Acting Reversible Contraceptive Market Size, Share & Trends." 2022.
[3] U.S. Food and Drug Administration. "Medical Devices." 2022.
[4] European Medicines Agency. "Contraceptive Devices." 2022.
[5] PatentScope. "Patent filings for intrauterine devices." WIPO. 2023.
